Verrica Pharmaceuticals Inc.
Close on Oct 19, 2026
- Market cap
- $73.29M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $5.90M | $-0.62 | $-0.48 |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | During market hours | $5.00M | $-0.45 | $-0.41 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 11, 2026 | Before market open | $5.09M | $-0.57 | $-0.51 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | During market hours | $14.30M | $-0.03 | $0.13 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | During market hours | $12.70M | $0.02 | $0.25 |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | – | – | $-0.08 |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 11, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | During market hours | -$1.78M | $-0.49 | $-0.43 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | Before market open | – | – | – |
Press releases
Announcements Verrica Pharmaceuticals filed with the SEC
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Announces Private Placement Financing of $50
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Verrica Announces Pricing of $42.0 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Verrica Announces Proposed Public Offering
Other events · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Company Overview August 2024 Exhibit
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Verrica Pharmaceuticals Announces Amendment to Companys Collaboration and License Agreement with
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Not For Promotional Use Disclaimer Certain information contained in this
Regulation FD disclosure · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Company Overview July 2023 Copyright
Regulation FD disclosure · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Announces FDA Approval of YCANTH
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Approval Call July 24, 2023 Copyright © 2023 Verrica Pharmaceuticals. All rights reserved. Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Following FDA Approval of YCANTH for the
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
Copyright © 2023 Verrica Pharmaceuticals. All rights reserved. Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Company Overview September 14, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Verrica Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Verrica Announces Pricing of Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Company Overview April 7, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Company Overview November 29, 2021
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K